How Rapid-Acting Antidepressants Are Changing Lives: Insights by Gerhard & Duman (2018)
Introduction: Antidepressants usually take weeks to work, but recent research by Dr. Gerhard and Dr. Duman explores rapid-acting treatments that […]
Introduction: Antidepressants usually take weeks to work, but recent research by Dr. Gerhard and Dr. Duman explores rapid-acting treatments that […]
Introduction: In 2020, Peyrovian and colleagues published an analysis of registered clinical trials investigating ketamine as a treatment for psychiatric
Introduction: In 2020, Dr. Eric Lenze and his team launched a pilot study to explore how ketamine might help older
Introduction: In 2019, a team of experts published an article in The New England Journal of Medicine highlighting the significance
Introduction: In 2019, the FDA approved esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). This report by
Introduction: The FDA reviewed a new treatment called esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). TRD
Introduction: The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and effectiveness of medications.
Introduction: Ketamine and esketamine have been explored in medical research for treating treatment-resistant depression (TRD), a severe form of depression
Introduction A recent study by Vekhova, Namiot, Jonsson, and Schiöth (Oct 2024) explores the growing use of ketamine and esketamine
Introduction: In 2020, Peyrovian and colleagues published an analysis of registered clinical trials investigating ketamine as a treatment for psychiatric